Detalles de la búsqueda
1.
Real-world utilization, patient characteristics, and treatment patterns among men with localized prostate cancer tested with the 17-gene genomic prostate score® (GPSTM) assay.
Prostate
; 84(10): 922-931, 2024 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-38666513
2.
Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy.
Oncologist
; 25(2): e243-e251, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32043763
3.
Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2-metastatic breast cancer receiving single-agent chemotherapy-a comparison with MONARCH 1.
Breast Cancer Res Treat
; 184(1): 161-172, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32789591
4.
Real-world patient-reported outcomes of women receiving initial endocrine-based therapy for HR+/HER2- advanced breast cancer in five European countries.
BMC Cancer
; 20(1): 855, 2020 Sep 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32894087
5.
Quality of life analysis of patients treated with cetuximab or cisplatin for locoregionally advanced squamous cell carcinoma of head and neck in the United States.
Health Qual Life Outcomes
; 18(1): 195, 2020 Jun 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-32571349
6.
Comprehensive review of factors implicated in the heterogeneity of response in depression.
Depress Anxiety
; 29(4): 340-54, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-22511365
7.
Obesity in relation to endometrial cancer risk and disease characteristics in the Women's Health Initiative.
Gynecol Oncol
; 121(2): 376-82, 2011 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21324514
8.
Treatment patterns for patients with advanced/metastatic cancers by site of care.
Am J Manag Care
; 27(4): e105-e113, 2021 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33877777
9.
Predicting optimal treatment regimens for patients with HR+/HER2- breast cancer using machine learning based on electronic health records.
J Comp Eff Res
; 10(9): 777-795, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33980048
10.
Development of a Prognostic Factor Index Among Women With HR+/HER2- Metastatic Breast Cancer in a Community Oncology Setting.
Clin Breast Cancer
; 21(4): 317-328.e7, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33678566
11.
KRAS mutation as a prognostic factor and predictive factor in advanced/metastatic non-small cell lung cancer: A systematic literature review and meta-analysis.
Cancer Treat Res Commun
; 24: 100200, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32750661
12.
Treatment patterns, survival and economic outcomes in Medicare-enrolled, older patients with HR+/HER2- metastatic breast cancer.
Curr Med Res Opin
; 35(10): 1699-1710, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31060392
13.
The Budget Impact of Including Necitumumab on the Formulary for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer: U.S. Commercial Payer and Medicare Perspectives.
J Manag Care Spec Pharm
; 24(6): 534-543, 2018 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-29799326
14.
Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial.
Clin Lung Cancer
; 19(3): 270-279.e3, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29373274
15.
Real-World Treatment Sequences and Outcomes Among Patients With Non-Small Cell Lung Cancer (RESOUNDS) in the United States: Study Protocol.
JMIR Res Protoc
; 6(10): e195, 2017 Oct 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-29021129
16.
Real-World Treatment Patterns among Patients with Advanced Gastric Cancer in South Korea.
Cancer Res Treat
; 49(3): 578-587, 2017 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-27618820
17.
Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer.
Lung Cancer
; 112: 126-133, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29191585
18.
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer.
Lung Cancer
; 112: 181-187, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29191593
19.
Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy.
Lung Cancer
; 93: 95-103, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26898621
20.
KRAS testing of patients with metastatic colorectal cancer in a community-based oncology setting: a retrospective database analysis.
J Exp Clin Cancer Res
; 34: 29, 2015 Mar 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-25888436